pharmaphorum January 21, 2025
Phil Taylor

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer’s, but an increase in some other conditions like kidney stones, low blood pressure, arthritis and joint pain, and pancreatitis.

Those are the findings of an observational study that claims to be the largest ever conducted on the drug class – based on 2.4 million people in the US Department of Veterans Affairs health record databases, including a cohort of 215,000 treated with GLP-1RAs – and has been published in the journal Nature Medicine.

It compared health outcomes among patients taking GLP-1RAs like Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide for diabetes and obesity to ‘usual care’ – in...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Clinical Trials, Patient / Consumer, Pharma / Biotech, Provider, Trends
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
CVS Caremark taps Omada on GLP-1 program
InnovationRx: Trump Administration Health Agency Layoffs Threaten Biotech Innovation
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
PBMs push private-label biosimilars in 2025 formularies

Share This Article